

This is an abridged prospectus containing salient features of the Prospectus. You are encouraged to read greater details available in the Prospectus.

THE DOCUMENT CONSISTS OF FOUR PAGES OF APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

You may obtain a physical copy of the Application form and the Prospectus from Stock Exchange, Registrar to the Issue, Share Transfer Agents, Depository Participants, Stock Brokers, Underwriters, Bankers to the Issue, Investors' Associations or Self Certified Syndicate Banks. You may also download the Prospectus from the websites of SEBI, Stock Exchange and Lead Manager; that is www.sebi.gov.in; www.bseindia.com and www.afsl.co.in



FABINO LIFE SCIENCES LIMITED

CIN: U24100DL2011PLC226781

Registered Office: 105, 1st Floor, Barodia Tower, Plot No 12, D Block, Central Market, Prashant Vihar, New Delhi 110085

Corporate Office: B-Wing, Shubham Garden Complex, Murthal Road, Sonapat, Haryana- 131001,

Tel No.: +91 – 9883900021/9215324221; **Email:** info@fabinolife.com; **Website:** www.fabinolife.com

Contact Person: Jeel Poshiya, Company Secretary and Compliance Officer.

PROMOTER OF OUR COMPANY

Atul Kumar Jain

ISSUE DETAILS, LISTING AND PROCEDURE

Initial Public Issue of 9,00,000 equity shares of ₹ 10 each (“Equity Shares”) of Fabino Life Sciences Limited (“FLSL” or the “Company”) for cash at a price of ₹ 36 per share (the “Issue Price”), aggregating to ₹ 324.00 lakhs (“the Issue”), of which 48,000 equity shares of ₹10 each will be reserved for subscription by Market Maker to the Issue (the “Market Maker Reservation Portion”). The Issue less the Market Maker reservation portion i.e. Issue of 8,52,000 equity shares of ₹ 10 each is hereinafter referred to as the “Net Issue”. The Issue and the Net Issue will constitute 42.86% and 40.57%, respectively of the Post Issue paid up equity share capital of the Company

These Equity Shares are proposed to be listed on the SME Platform of BSE Limited.

This IPO being Fixed Price Issue, the price per Equity Share is been fixed at ₹ 36 per share of Face value of ₹ 10 each and the minimum application size is 3,000 Equity Shares and in multiple of 3,000 Equity Shares thereafter and for which Pre-Issue advertisement shall be advertised in all editions of Business Standard (a widely circulated English national newspaper) and all editions of Business Standard (Hindi) (a widely circulated Hindi national newspaper). For details about the “Basis for Issue Price”, please refer page 63 of the Prospectus.

Procedure:

If you wish to know about processes and procedures applicable to public issues, you may request for a copy of the General Information Document from Lead Manager (LM) or download it from the websites of BSE at www.bseindia.com and the LM www.afsl.co.in

ELIGIBILITY FOR THE ISSUE

Whether the company is compulsorily required to allot at least 75% of the Net Issue to public, to QIBs – **No** This being an Issue under Chapter IX of SEBI (ICDR) Regulations, 2018. The Company is Eligible for the Issue in terms of Regulation 229(1) of SEBI (ICDR) Regulations, 2018.

INDICATIVE TIMETABLE

Issue Opening Date	December 31, 2021	Initiation of Allotment / Refunds / Unblocking of Funds	on or before January 11, 2022
Issue Closing Date	January 05, 2022	Credit of Equity Shares to Demat accounts of Allotees	on or before January 12, 2022
Finalisation of Basis of Allotment with the Designated Stock Exchange	on or before January 10, 2022	Commencement of trading of Equity Shares on the Stock Exchanges	on or before January 13, 2022

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Company and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Prospectus. Specific attention of the investors is invited to “Risk Factors” at page 18 of the Prospectus and on page 7 of this Abridged Prospectus.

PRICE INFORMATION OF LEAD MANAGER

PRICE INFORMATION OF ARYAMAN FINANCIAL SERVICES LIMITED

Issue Name	Name of the Merchant Banker	+/- % change in closing price, +/- % change in closing benchmark		
		30 th calendar days from listing	90 th calendar days from listing	180 th calendar days from listing
Suyog Gurbaxani Funicular Ropeways Ltd	Aryaman Financial Services Limited	12.44% [-4.01%]	N.A.	N.A.
CWD Ltd.		30.39% [-0.08%]	N.A.	N.A.
Gretex Corporate Services Ltd.		9.38% [7.07%]	19.29% [10.41%]	N.A.
Times Green Energy (India) Ltd.		0.08% [0.20%]	3.28% [13.69%]	N.A.
Adeshwar Meditex Ltd.		0.20% [-0.55%]	14.00% [13.87%]	44.20% [8.32%]
Pavna Industries Ltd.		0.06% [-1.49%]	1.21% [4.33%]	9.09% [14.74%]
Net Pix Shorts Digital Media Ltd.		0.83% [7.29%]	0.17% [12.73%]	14.50% [8.80%]

Notes:

- Since the listing date of Suyog Gurbaxani Funicular Ropeways Limited and CWD Limited on November 16, 2021 and October 13, 2021, information related to closing price and benchmark index as on the 90th and 180th Calendar day from the listing date is not available.
- Since the listing dates of Times Green Energy (India) Limited and Gretex Corporate Services Limited was on June 30, 2021 and August 09, 2021, information related to closing price and benchmark index as on the 180th Calendar day from the listing date is not available.
- The respective Designated Stock Exchange for each Issue has been considered as the Benchmark index for each of the above Issues.
- In the event any day falls on a holiday, the price/index of the immediate preceding working day has been considered. If the stock was not traded on the said calendar days from the date of listing, the share price is taken of the immediately preceding trading day.
- Source: www.bseindia.com and www.nseindia.com BSE Sensex and Nifty Fifty as the Benchmark Indices
- Disclosures subject to 7 recent issues (initial public offerings) in current financial year and two preceding financial years managed by the Merchant Bankers

Names of Lead Manager and contact details (Telephone and Email ID)	Aryaman Financial Services Limited 60, Khatau Building, Gr. Floor, Alkesh Dinesh Modi Marg, Fort, Mumbai - 400 001, Maharashtra, India Tel. No.: +91- 22 - 6216 6999; Email: ipo@afsl.co.in; Website: www.afsl.co.in Investor Grievance Email: feedback@afsl.co.in Contact Person: Vastal Ganatra
Name of Registrar to the Issue and contact details (Telephone and Email ID)	Bigshare Services Private Limited 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis Makwana Road, Marol, Andheri East, Mumbai – 400 059 Tel. No.: +91 – 22 – 6263 8200; Email: ipo@bigshareonline.com; Website: www.bigshareonline.com; Investor Grievance Email: investor@bigshareonline.com; Contact Person: Babu Raphael
Name of Statutory Auditor	M/s. D G M S & Co.
Name of Credit Rating Agency and the rating or grading obtained, if any	NA
Name of Debenture trustee, if any	NA

Self Certified Syndicate Banks: The list of SCSBs notified by SEBI for the ASBA process is available at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes on the SEBI website, or at such other website as may be prescribed by SEBI from time to time. A list of the Designated Branches of the SCSBs with which an ASBA Applicant (other than an RII using the UPI mechanism), not Applying through Syndicate or through a Registered Broker, may submit the ASBA Forms is available at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 on the SEBI website, and at such other websites as may be prescribed by SEBI from time to time.

Further, the branches of the SCSBs where the Designated Intermediaries could submit the ASBA Form(s) of Applicants (other than RIIs) is provided on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35> which may be updated from time to time or at such other website as may be prescribed by SEBI from time to time

Registered Brokers: The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the websites of the BSE at http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?, as updated from time to time

Details regarding website address(es)/link(s) from which the investor can obtain list of Registrar to Issue and share transfer agents and depository participants who can accept application from investor (as applicable):
The details of the Designated Registrar and Share Transfer Agents Locations and Designated Collecting Depository Participant Locations, along with their names and contact details are available on the website of the Stock Exchange (www.bseindia.com) and updated from time to time.

PROMOTER OF OUR COMPANY

Atul Kumar Jain

Atul Kumar Jain, aged 53 years, is the Chairman & Managing Director and Promoter of our Company. He was appointed on the Board of our Company upon incorporation i.e. w.e.f October 27, 2011. He has obtained degree in Bachelors of Commerce in the year 1988 from Maharshi Dayanand University and started his career with a family business of Brick Kelling, Trading of Coal and Mining of SlikaSina. He has also run various other businesses like real estate, hospitality and Automobiles. In 2011, he ventured into pharmaceutical sector with Fabino Life Sciences Limited; He is responsible of the overall growth and development of our Company and for taking all key decisions in consultation with the Board. He is also the Managing Director of Vaksons Automobiles Limited.

None of our Group Companies is listed on any Stock Exchange.

BUSINESS MODEL / BUSINESS OVERVIEW AND STRATEGY

Business Overview:

We are a growing pharmaceutical and other wellness focused consumer Products Company operating from Delhi and Haryana. Our company emphasizes developing high-quality and affordable products for all sections of society by harnessing the skills of our competent manpower and other resources. We aim at providing the best quality products at affordable rates for good health and well-being for all.

Fabino Life sciences Ltd is engaged in manufacturing, marketing, trading and Packing of pharmaceutical and other wellness focused consumer products, Our core business is marketing of Pharmaceutical formulation & products in Domestic market through own distribution network and Sales force under own brand name, Getting our Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labeling etc. We export wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which are marketed by our company.

Our Ayurvedic/Herbal business operations are supported by loan licensing facilities which are approved by relevant authorities. We typically enter into Loan License Agreement for periods ranging from one to five years. We have been awarded a G.M.P Certification for following Good Manufacturing Practices of Ayurveda/Siddha/Unnani drugs under “Schedule T” of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, capsule, Oils, Syrups and Powder.

Our company is the brainchild of our promoter “Atul Kumar Jain” who has been the guiding force behind our growth. Backed by his 15 plus years of experience our promoter has been instrumental in shaping the value systems of our company. We value our customers and aim to exceed the expectations of our customers by offering diverse products and fulfilling valuable commitments. We currently have over 70 launched and active products in multiple categories available in markets as entailed below:

- Allopathic
- Covid 19
- Food & Wellness
- Herbal
- Veterinary
- Multi-Vitamin

Our product range is bifurcated into brands as under:

Fabino is the Brand under which we market all of our pharmaceutical products including Tablets, Ointments Syrups etc for various medical treatments in our allopathic and certain herbal range.

Keepshine is the Brand under which we market our Shampoo and Hair Maintenance products.

We aim at tapping strong distribution network in medical or pharmaceutical field in the future. Further, Our Promoter has obtained registrations and patents for various products. Some of these products are manufactured by us in house at our processing centre in Sonipat Haryana, some of our products are manufactured at our contract manufacturing facility in Haryana and other product range is manufactured by third party manufacturers on made to order basis as per our instructions.

Our Strategy:

- Increase in Order-taking Appetite by augmenting our working capital base
- Geographical Diversification
- Digital Marketing

BOARD OF DIRECTORS

Sr. No.	Name	Designation	Experience including current/past position held in other firms
1.	Atul Kumar Jain	Chairman & Managing Director	For details please refer to page no. 5 of this Abridged Prospectus.
2.	Aditya Mahavir Jain	Non Executive Director	He worked as intern at Food Art Hospitality, RDH Event Management, Ancalima Lifesciences. He is making & maintaining cordial relations with various players in medical field and also assists in Digital Marketing and logistics, Exporting coffee and malt protein.
3.	Arihant Jain	Non Executive Director	He holds B.Tech and MBA degree. He worked with ICICI bank as Marketing and Research Analysis. He is currently in his family business of Stainless Steel and Import of Dry Fruits & Nuts. He has over 10 years experience.
4	Kuldeep Solanki	Non Executive Independent Director	He Holds LLB degree. He started his own practice as Lawyer named as KS & Company from the year 1998. He has an experience of over 23 years.
5	Tesu Alakh	Non Executive Independent Director	She completed bachelors of Science and Master's in English Literature. She is working as freelancer for selling of Insurance and Partner at Investmitraa Finserv IMF LLP. She is currently looking after the Finance aspect of Investmitraa Finserv IMF LLP
6	Gagan Gupta	Non Executive Independent Director	He completed his Bachelors of Engineering from Maharshi Dayanand University in the year 2009. Prior to joining our Company, he was associated with Hiko logistics Private Limited and Talecome Talbros Automated Co. Ltd. He has experience of over 12 years.

OBJECTS OF THE ISSUE

The details of the proceeds of the Issue are set below:

1. Part Repayment of Loans
2. Funding Working capital requirements
3. General Corporate Purpose

The details of the proceeds of the Issue are set forth in the table below

(Rs. in lakhs)

Sr. No.	Particulars	Amount
1	Gross Proceeds from the Issue	324.00
2	Less: Issue related expenses	43.66
	Net Proceeds from the Issue	280.34

The fund requirements for each of the Object of the Issue are stated as below:

(Rs. in lakhs)

Sr. No.	Objects of the Issue	Total Funds Required	Amount Deployed till Date	Amount to be financed from Net Proceeds of Issue	Estimated Net Proceeds Utilization in FY 2021-22
1	Part Repayment of Loans	25.00	Nil	25.00	25.00
2	Funding Working capital requirements	204.90	Nil	204.90	204.90
3	General Corporate Purpose	50.44	Nil	50.44	50.44
	Total	280.34	Nil	280.34	280.34

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues/rights issues, if any, of the Company in the preceding 10 years – Not Applicable

Name of monitoring agency, if any – Not Applicable

Terms of Issuance of Convertible Security, if any – Not Applicable

Shareholding Pattern

Sr. No.	Particulars	Pre Issue Number of Shares	% holding of Pre-Issue	Post Issue Number of Shares*	% holding of Post-Issue
1.	Promoter and Promoter Group	11,93,200	99.43%	11,93,200	56.82%
2.	Public	6,800	0.57%	9,06,800	43.18%
	Total	12,00,000	100.00%	21,00,000	100.00%

*Assuming full subscription in the Issue.

Number of Equity Shares to be sold by the Selling Shareholder by way of Offer for sale: Nil

RESTATED AUDITED FINANCIALS

(₹ in lakhs)

Particulars	As at June 30, 2021	For the year ended March 31,		
		2021	2020	2019
Total income from operations (net)	112.90	305.92	751.69	276.16
Net Profit / (Loss) before tax and extraordinary items	1.95	4.26	9.91	0.33
Net Profit / (Loss) after tax and extraordinary items	1.95	4.26	9.91	0.33
Equity Share Capital	120.00	120.00	15.00	15.00
Reserves & Surplus	11.70	10.27	52.26	45.37
Net Worth	131.70	130.27	67.26	60.37
Earnings Per Share:				
Basic (Rs)	0.12	0.50	1.15	-
Diluted (Rs)	0.12	0.50	1.15	-
Return on Net Worth (%)	1.08%	2.32%	10.24%	0.02%
Net Asset Value Per Share (Rs)	10.97	10.86	44.84	40.25

INTERNAL RISK FACTORS

Below are the top 10 Risk Factors as per the Prospectus:

1. There are outstanding litigation proceedings filed by Our Company. Any adverse outcome in such proceedings may have an adverse impact on our reputation, business, financial condition, results of operations and cash flows:
2. Substantial portion of our revenues has been dependent upon limited number of customers and we do not have firm commitment supply agreements with our customers. If our customers choose not to source their requirements from us, our business and results of operations may be adversely affected.
3. Our reliance on third parties for certain aspects of our business like transportation and logistics exposes us to certain risks.
4. Our operations have significant raw material requirements, and we may not be able to ensure the availability of the raw materials at competitive prices, which may adversely affect results of our operations.
5. Our Company has taken unsecured loans that may be recalled by the Directors cum Promoter or relative of directors at any time.
6. Our business largely depends on the performance of our distributors.
7. We do not own our registered office, Corporate Office or Manufacturing unit facility from which we carry out our business activities.
8. The continuing effect of the COVID-19 pandemic on our business and operations is highly uncertain and cannot be predicted.
9. We intend to repay certain loan facilities availed from our Director from the IPO Proceeds.
10. If we are unable to compete successfully with our competitors, our market position and profitability could be adversely impacted.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

- A. Total number of outstanding litigations against our Company and the amount involved:
 - 1. No. of Case: 1
 - 2. Amount Involved: NIL
- B. Brief details of top 5 material outstanding litigations against our Company and amount involved: There are no outstanding litigations filed against us and hence no amount is involved.
- C. No regulatory or disciplinary action has been taken by SEBI or stock exchanges against the Promoters/ Group Companies in last 5 financial years.
- D. **Brief details of outstanding criminal proceedings against our Promoter:** There is no outstanding criminal proceedings against our Promoter

ANY OTHER IMPORTANT INFORMATION AS PER LEAD MANAGER / COMPANY - NIL

DECLARATION BY THE COMPANY

We, hereby declare that, all the relevant provisions of the Companies Act, 1956, Companies Act, 2013 (to the extent notified) and the guidelines issued by the Government of India or the regulations or guidelines issued by the Securities and Exchange Board of India, as the case may be, have been complied with and no statement made in the Prospectus is contrary to the provisions of the Companies Act, 1956, Companies Act, 2013 (to the extent notified), the Securities and Exchange Board of India Act, 1992, each as amended or rules made there under or guidelines / regulations issued, as the case may be. We further certify that all the disclosures and statements made in the Prospectus are true and correct.